Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKNE-MYCIN vs BACIGUENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
Topical treatment of acne vulgaris
Topical treatment of superficial skin infections caused by susceptible strains of Staphylococcus spp., Streptococcus spp., and other gram-positive bacteria,Prophylaxis of minor skin infections,Off-label: Prevention of infection in minor cuts, scrapes, and burns
Topical application of 2% solution twice daily to affected areas.
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Bacitracin undergoes minimal systemic absorption via topical application; not significantly metabolized; excreted unchanged in urine if absorbed.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
Bound primarily to albumin (10-20%)
Approximately 20–30% bound to serum proteins, mainly albumin
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
0.25–0.4 L/kg (total body water); limited tissue distribution, primarily extracellular fluid
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
Topical: negligible systemic absorption (<0.5%) through intact skin; oral: not absorbed (inactivated in GI tract; not used systemically)
No dosage adjustment required for topical use; systemic absorption negligible.
No dose adjustment required for topical use; systemic absorption is minimal.
No dosage adjustment required for topical use; systemic absorption negligible.
No dose adjustment required for topical use.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
Apply thin layer to affected area 1 to 3 times daily; safety in infants under 2 months not established.
No specific adjustments; use with caution due to potential increased skin sensitivity.
No specific dose adjustment; use same as adult dosing.
None
Due to nephrotoxicity, bacitracin is NOT recommended for parenteral use; topical use only.
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Hypersensitivity reactions including anaphylaxis,Prolonged use may result in overgrowth of non-susceptible organisms, including fungi,Avoid contact with eyes,Not for use on deep wounds or severe burns
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
Hypersensitivity to bacitracin or any component of the formulation
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
No known food interactions with topical bacitracin. Avoid ingestion.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contraindicated due to nephrotoxicity, and limited data exist for systemic use in pregnancy. Animal studies show no evidence of harm, but human data are insufficient.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
Bacitracin is not systemically absorbed from topical use; therefore, breast milk exposure is negligible. M/P ratio is not applicable. Considered safe during breastfeeding when used topically. For systemic use, avoid due to potential nephrotoxicity.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
No dosing adjustment needed for topical bacitracin. Systemic use is contraindicated in pregnancy due to risk of maternal nephrotoxicity; if unavoidable, use with extreme caution and monitor renal function, but no specific dose recommendations exist.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
Bacitracin is a topical polypeptide antibiotic effective against gram-positive organisms. It is often combined with neomycin and polymyxin B in triple antibiotic ointments. For minor wounds, apply a thin layer 1-3 times daily. Avoid use on large body surface areas or for deep puncture wounds due to risk of systemic absorption and nephrotoxicity. Monitor for allergic contact dermatitis, especially with prolonged use.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
Clean the affected area before each application.,Apply a thin layer of ointment 1 to 3 times daily.,Do not use on large areas of the body, deep wounds, or animal bites.,Stop use and consult a doctor if the condition worsens or does not improve within 1 week.,Avoid contact with eyes or mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKNE-MYCIN vs BACIGUENT, answered by our medical review team.
AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. BACIGUENT is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKNE-MYCIN and BACIGUENT depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. The standard adult dose of BACIGUENT is: Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKNE-MYCIN and BACIGUENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . BACIGUENT is classified as Category C. Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contrai. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.